Murugesan, AkshayaHolmstedt, SuviBrown, Kenna C.Koivuporras, AlisaMacedo, Ana S.Nguyen, NgaFonte, PedroRijo, PatriciaYli-Harja, OlliCandeias, Nuno R.Kandhavelu, Meenakshisundaram2021-06-242021-06-242020-111756-8919http://hdl.handle.net/10400.1/16356Aim: Quinic acid (QA) is a cyclic polyol exhibiting anticancer properties on several cancers. However, potential role of QA-derivatives against glioblastoma is not well established. Methodology & results: Sixteen novel QA-derivatives and QA-16 encapsulated poly (lactic-co-glycolic acid) nanoparticles (QA-16-NPs) were screened for their anti-glioblastoma effect using standard cell and molecular biology methods. Presence of a tertiary hydroxy and silylether groups in the lead compound were identified for the antitumor activity. QA-16 have 90% inhibition with the IC50 of 10.66 mu M and 28.22 mu M for LN229 and SNB19, respectively. The induction of apoptosis is faster with the increased fold change of caspase 3/7 and reactive oxygen species. Conclusion: QA-16 and QA-16-NPs shows similar cytotoxicity effect, providing opportunity to use QA-16 as a potential chemotherapeutic agent.engChemotherapeutic drugsCytotoxicityGlioblastomaNanoparticlePLGAQuinic acidPharmacology & Pharmacyjournal article10.4155/fmc-2020-0194